title: Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration.
abstract: The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.
authors.affiliation: Division of Nutrition Programs and Labeling, US Food and Drug Administration, College Park, Maryland, USA. Paula.Trumbo@FDA.gov
authors.forename: Paula R
authors.initials: PR
authors.lastname: Trumbo
authors.forename: Kathleen C
authors.initials: KC
authors.lastname: Ellwood
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology* / Q000517:prevention & control; D019587:Dietary Supplements; D019317:Evidence-Based Medicine; D005515:Food Labeling; D006801:Humans; D007333:Insulin Resistance; D010848:Picolinic Acids / Q000627:therapeutic use*; D012307:Risk Factors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001786:Blood Glucose; D010848:Picolinic Acids; C030614:picolinic acid